Clinical Trial Detail

NCT ID NCT03454451
Title CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Corvus Pharmaceuticals, Inc.
Indications

renal cell carcinoma

triple-receptor negative breast cancer

urinary bladder cancer

colorectal cancer

uterine cancer

sarcoma

prostate cancer

cervical cancer

endometrial cancer

lung non-small cell carcinoma

Therapies

CPI-006

CPI-006 + Pembrolizumab

CPI-006 + CPI-444

Age Groups: senior adult

Additional content available in CKB BOOST